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gested by these clinical experts. The resulting health states (n =
17) were piloted and used in a societal-based valuation study 
(n = 100). Participants rated half of the total health states in a
standard gamble interview to derive health state utility scores.
Data were analysed using a mixed model analysis. This study
was conducted in line with standard NICE appraisal methodol-
ogy. RESULTS: All tumour response statuses and toxicities were
independent signiﬁcant predictors of utility (p < 0.001). Stable
disease with no toxicity (our base state) had a utility value of
0.65. Utility scores ranged from 0.67 (responding disease with
no toxicity) to 0.47 for progressive disease. CONCLUSION:
This study reﬂects the value that society places on the avoidance
of disease progression and severe toxicities associated with the
treatment of second-line advanced NSCLC.
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OBJECTIVES: Assess inter-rater agreement (patient and parent)
of HUI utility scores for survivors of brain tumors in childhood.
METHODS: Patients and their parents were interviewed twice
using an interviewer-administered HUI questionnaire. Agree-
ment was assessed using intra-class correlation coefﬁcients
(ICC). T-tests assessed the statistical signiﬁcance of differences in
mean overall and pain utility scores between patients reporting
no pain and those reporting pain. RESULTS: HUI data for 40
brain tumor survivors (57.5% female) were collected during late
2000 and early 2001 (interview 1). To date, 26 re-assessment
interviews have been completed during 2005–2006 (interview 2).
One patient has died. Patient mean age was 6.8 years at diag-
nosis and 16.2 years at the ﬁrst survey. For overall health-related
quality of life scores (HRQL), there was substantial inter-rater
agreement (HUI3 ICC = 0.723, p < 0.001) at interview 1 and
moderate agreement (HUI3 ICC = 0.561, p = 0.03) at interview
2. There was substantial to almost perfect agreement at both
interviews for attributes considered readily observable (vision,
speech, ambulation and dexterity) (ICC 0.783 to 0.988, p <
0.001). For less observable attributes (emotion, cognition, pain),
agreement was moderate or less (ICC from 0.101 to 0.611, p =
0.372 to 0.002). Statistically signiﬁcant differences were detected
for both mean HRQL (difference = 0.36, p = 0.003) and pain
(difference = 0.24, p = 0.003) scores between patients reporting
pain (n = 14) and those pain free at interview 1. At interview 2,
the mean scores were not statistically signiﬁcantly different
between patients reporting pain (n = 7) and those with no pain
(n = 19, HRQL p = 0.317; pain attribute p = 0.067). CON-
CLUSIONS: There was moderate or better inter-rater agreement
for HRQL and all readily observable single-attribute HUI3
scores both at interview 1 and interview 2. Levels of ICC are
consistent with previous studies of childhood cancer survivors in
Brazil and Uruguay. Differences in mean HRQL and pain scores
between patients with and without pain is evidence of discrimi-
native validity.
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OBJECTIVES: Assess the reliability and validity of a newly
developed patient-reported outcome (PRO) questionnaire for
metastatic colorectal cancer (mCRC) patients. METHODS: The
questionnaire, which includes ﬁve scales [NCCN/FACT Col-
orectal Cancer Scale (CS), De Novo Bother Life Quality Index
(DNB), EORTC QLQ-C30 Global Quality of Life Subscale
(EORTC), EQ-5D Index Scale (EQ-5D) and the EQ-5D visual
analog scale (VAS)], was administered every four weeks to
mCRC patients in a Phase III clinical trial. Its psychometric prop-
erties were evaluated, including internal consistency reliability,
test-retest reliability, construct validity, known groups validity,
and responsiveness. RESULTS: A total of 391 mCRC patients
completed the questionnaire at baseline and at least one follow-
up assessment. Internal consistency was demonstrated with
Cronbach’s alphas for all scales >0.70 (range: 0.81–0.92). The
4-week test-retest reliability, as measured by the intra-class 
correlation, among patients who had stable EQ-5D scores and
also among patients whose ECOG performance status was
unchanged, ranged from 0.58–0.76 and 0.61–0.76, respectively.
Construct validity was demonstrated based on proposed inter-
scale correlations being borne out [e.g., CS was highly correlated
with EORTC (0.72)]. Known groups validity was evaluated by
examining the scale scores of patients categorized by their ECOG
performance status. Other than DNB, patients with better per-
formance status reported better scores than those with a lower
performance status (ECOG = 0 or 1 vs. 2). Signiﬁcant differences
were reported on all scales (p < 0.001) at baseline and week 8
with the exception of DNB. Responsiveness, as measured by
Guyatt’s statistic, was >0.20 for all scales from baseline to week
8 (range 0.56–1.13) and from weeks 4 to 12 (range 0.29–1.11).
EORTC and EQ-5D Index scales were the most responsive.
CONCLUSIONS: Results provide preliminary evidence of the
reliability, validity, and responsiveness of the questionnaire.
Additional work is needed to estimate the minimal clinical
important difference and more fully investigate test-retest 
reliability.
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OBJECTIVE: We examined demographics, clinical characteris-
tics, Health Related Quality of Life (HRQoL) and satisfaction
with care across two treatments (radical prostatectomy or RP
and external beam radiation or EBRT) for older prostate cancer
(PCa) patients. METHODS: In this prospective cohort study we
recruited 215 newly diagnosed PCa patients, 65 years or older,
from the urology clinics of an urban academic hospital and a VA
hospital. Patients completed generic (SF-36), prostate speciﬁc
(UCLA-PCI) HRQoL, and satisfaction with care (CSQ-8)
surveys prior to treatment and at 3, 6, and 12 months post-
treatment. Clinical and demographic data were obtained using
hospital based databases. Repeated measures ANOVA was used
to examine changes in generic and PCa speciﬁc HRQoL across
treatments. Log-linear regression was used to determine factors
associated with 12 month HRQoL. Survival curves were used to
